Amgen postpones analysts meeting
Executive Summary
Amgen has rescheduled its annual business review from Nov. 21 to Feb. 25, citing uncertainty surrounding the "re-launch" of Enbrel with increased supply; the pending appeal of EPO patent litigation versus TKT; and the OPPS coverage decision for Aranesp...